Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Global Cord Blood Corporation (CORBF)
USD0.95
+0.00 (+0.00%)
HK OTC Healthcare Medical - Diagnostics & Research
Address
Bank of China Tower
Central, HK
Central, HK
CEO
Ting Zheng
Website
globalcordbloodcorp.com
IPO
2007-05-09
CIK 1467808 ISIN KYG393421030
Also trades on
New York Stock Exchange · CO (USD)
Other OTC · CORBF (USD)
Description
Global Cord Blood Corporation, headquartered in Central, Hong Kong, primarily offers umbilical cord blood preservation and related support services within the People's Republic of China. The company's operations include the comprehensive testing, processing, and long-term storage of cord blood samples for its individual clients. Additionally, it undertakes the examination, preparation, and storage of donated cord blood units, facilitating their use for matching purposes. As of March 31, 2022, the corporation oversaw the management of three distinct cord blood banks, located in Beijing municipality, Guangdong province, and Zhejiang province. The entity previously operated as China Cord Blood Corporation, adopting its current name in March 2018, and functions as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.95
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
15.5K
Beta
-0.77
Float Shares
116.52M
Free Float %
87.0%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.00% | -5.00% | +0.00% | +0.00% | -14.41% | +0.00% | -5.00% | -68.23% | -84.65% | -84.38% | -82.73% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Hold
Price Targets & DCF
Current price
0.95
DCF (Unlevered)
38.95
+3,999.8%
DCF (Levered)
44.82
+4,617.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
4.63
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
7 / 10
Strong MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Diagnostics & Research: +7.9%+7.2% Q3'22: -5.7% (vs Q2'21)
-
EPS growth Medical - Diagnostics & Research: +30.8%-1.4% Q3'22: -21.4% (vs Q2'21)
-
FCF margin FCF growth · Medical - Diagnostics & Research: +32.2%+41.4% Q3'22: -0.1% (vs Q2'21)
-
EBIT margin Medical - Diagnostics & Research: +9.6%+49.0% ★ Q3'22: +47.8% (vs Q2'21)
-
ROIC Medical - Diagnostics & Research: +5.2%— Q3'22: -154.3% (vs Q2'21)
-
Share dilution Medical - Diagnostics & Research: 0.0%+0.0% ★ Q3'22: 0.0% (vs Q2'21)
-
Debt / EBITDA Net debt/EBITDA · Medical - Diagnostics & Research: -0.13×0.00× ★ Q3'22: 0.00× (vs Q2'21)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Mar 2015 actual |
Mar 2016 actual |
Mar 2017 actual |
Mar 2018 actual |
Mar 2019 actual |
Mar 2020 actual |
Mar 2023 actual |
Mar 2024 actual |
Mar 2025 actual |
Mar 2026 1 Rev. Ana. 1 EPS Ana. |
Mar 2027 1 Rev. Ana. 1 EPS Ana. |
Mar 2028 1 Rev. Ana. 1 EPS Ana. |
Mar 2029 1 Rev. Ana. 1 EPS Ana. |
Mar 2030 1 Rev. Ana. 1 EPS Ana. |
Mar 2031 1 Rev. Ana. 1 EPS Ana. |
Mar 2032 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
635.12M
est: 638.71M (-0.6%)
|
663.00M
est: 683.68M (-3.0%)
|
759.98M
est: 766.00M (-0.8%)
|
936.77M
est: 949.10M (-1.3%)
|
986.75M
est: 1.12B (-11.9%)
|
1.22B
est: 1.48B (-17.4%)
|
238.55B
est.
|
262.10B
est.
|
750.41M
est.
|
727.24M
727.24M – 727.24M
-3.1% YoY
|
765.72M
765.72M – 765.72M
+5.3% YoY
|
1.04B
1.04B – 1.04B
+35.7% YoY
|
1.15B
1.15B – 1.15B
+10.3% YoY
|
1.44B
1.44B – 1.44B
+25.3% YoY
|
238.83B
238.83B – 238.83B
+16,527.1% YoY
|
249.50B
249.50B – 249.50B
+4.5% YoY
|
| EBITDA |
306.33M
est: 300.95M (+1.8%)
|
299.10M
est: 322.14M (-7.2%)
|
333.71M
est: 360.93M (-7.5%)
|
353.60M
est: 447.21M (-20.9%)
|
434.02M
est: 527.77M (-17.8%)
|
608.48M
est: 697.07M (-12.7%)
|
112.40B
est.
|
174.68B
est.
|
500.10M
est.
|
484.66M
484.66M – 484.66M
-3.1% YoY
|
510.30M
510.30M – 510.30M
+5.3% YoY
|
692.72M
692.72M – 692.72M
+35.7% YoY
|
764.15M
764.15M – 764.15M
+10.3% YoY
|
957.28M
957.28M – 957.28M
+25.3% YoY
|
159.17B
159.17B – 159.17B
+16,527.1% YoY
|
166.28B
166.28B – 166.28B
+4.5% YoY
|
| EBIT |
256.22M
est: 271.77M (-5.7%)
|
249.30M
est: 290.91M (-14.3%)
|
285.73M
est: 325.94M (-12.3%)
|
306.79M
est: 403.84M (-24.0%)
|
381.66M
est: 476.60M (-19.9%)
|
559.03M
est: 629.48M (-11.2%)
|
101.50B
est.
|
168.31B
est.
|
481.88M
est.
|
467.01M
467.01M – 467.01M
-3.1% YoY
|
491.71M
491.71M – 491.71M
+5.3% YoY
|
667.48M
667.48M – 667.48M
+35.7% YoY
|
736.31M
736.31M – 736.31M
+10.3% YoY
|
922.41M
922.41M – 922.41M
+25.3% YoY
|
153.37B
153.37B – 153.37B
+16,527.1% YoY
|
160.22B
160.22B – 160.22B
+4.5% YoY
|
| Net Income |
107.29M
est: 180.33M (-40.5%)
|
90.97M
est: 149.43M (-39.1%)
|
126.19M
est: 125.53M (+0.5%)
|
237.10M
est: 361.97M (-34.5%)
|
291.12M
est: 365.55M (-20.4%)
|
470.72M
est: 493.83M (-4.7%)
|
1.59B
est.
|
1.81B
est.
|
211.87M
est.
|
158.95M
158.95M – 158.95M
-25.0% YoY
|
125.48M
125.48M – 125.48M
-21.1% YoY
|
396.43M
396.43M – 396.43M
+215.9% YoY
|
374.20M
374.20M – 374.20M
-5.6% YoY
|
479.49M
479.49M – 479.49M
+28.1% YoY
|
1.59B
1.59B – 1.59B
+232.0% YoY
|
1.72B
1.72B – 1.72B
+8.1% YoY
|
| SGA |
259.61M
est: 252.18M (+2.9%)
|
318.11M
est: 269.94M (+17.8%)
|
368.42M
est: 302.44M (+21.8%)
|
462.70M
est: 374.74M (+23.5%)
|
404.38M
est: 442.25M (-8.6%)
|
452.19M
est: 584.11M (-22.6%)
|
94.19B
est.
|
103.49B
est.
|
296.29M
est.
|
287.14M
287.14M – 287.14M
-3.1% YoY
|
302.33M
302.33M – 302.33M
+5.3% YoY
|
410.40M
410.40M – 410.40M
+35.7% YoY
|
452.72M
452.72M – 452.72M
+10.3% YoY
|
567.14M
567.14M – 567.14M
+25.3% YoY
|
94.30B
94.30B – 94.30B
+16,527.1% YoY
|
98.51B
98.51B – 98.51B
+4.5% YoY
|
| EPS |
1.36
est: 1.48 (-8.3%)
|
1.25
est: 1.23 (+1.7%)
|
1.59
est: 1.03 (+54.0%)
|
1.99
est: 2.98 (-33.2%)
|
2.40
est: 3.01 (-20.2%)
|
3.87
est: 4.06 (-4.7%)
|
13.08
est.
|
14.87
est.
|
1.74
est.
|
1.31
1.31 – 1.31
-25.0% YoY
|
1.03
1.03 – 1.03
-21.1% YoY
|
3.26
3.26 – 3.26
+215.9% YoY
|
3.08
3.08 – 3.08
-5.6% YoY
|
3.94
3.94 – 3.94
+28.1% YoY
|
13.10
13.10 – 13.10
+232.0% YoY
|
14.16
14.16 – 14.16
+8.1% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
149.35M
OE per share TTM
1.23
Owner's Yield
129.11%
Maintenance CapEx ratio
9.01%
Maint CapEx / Avg PPE
53.5%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
27
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Sanpower Group Co., Ltd. | 81.53M | 67.10% | — | 81.53M | — | 10.00 | CO | of China | 2022-09-23 | ↗ |
| 2 | Yafei Yuan | 81.53M | 67.10% | — | 81.53M | — | 10.00 | IN | of China | 2022-09-23 | ↗ |
| 3 | Co Ltd | 79.53M | 65.40% | — | 79.53M | — | 10.00 | CO | British Virgin Islands | 2022-09-23 | ↗ |
| 4 | Co., Ltd. | 79.53M | 65.40% | — | 79.53M | — | 10.00 | CO | People’s Republic of China | 2022-05-20 | ↗ |
| 5 | Co., Ltd. | 79.53M | 65.40% | — | 79.53M | — | 10.00 | CO | People’s Republic of China | 2022-06-03 | ↗ |
| 6 | Industry Investment Partnership (Limited Partnership) | 79.53M | 65.40% | — | 79.53M | — | 10.00 | PN | Peoples Republic of China | 2022-06-03 | ↗ |
| 7 | Management Co., Ltd. | 79.53M | 65.40% | — | 79.53M | — | 10.00 | CO | People’s Republic of China | 2022-09-23 | ↗ |
| 8 | Medical Industry Investment Partnership (Limited Partnership) | 79.53M | 65.40% | — | 79.53M | — | 10.00 | PN | People’s Republic of China | 2022-09-23 | ↗ |
| 9 | Sanpower Group Co., Ltd. | 79.53M | 65.40% | — | 79.53M | — | 10.00 | CO | People’s Republic of China | 2022-05-20 | ↗ |
| 10 | Golden Meditech Stem Cells (BVI) Company Limited | 78.87M | 64.90% | 78.87M | — | 78.87M | 10.00 | CO | British Virgin Islands | 2022-05-31 | ↗ |
| 11 | Kam Yuen | 78.87M | 64.90% | 78.87M | — | 78.87M | 10.00 | IN | Hong Kong S.A.R. | 2022-05-31 | ↗ |
| 12 | Magnum Opus International Holdings Limited | 78.87M | 64.90% | 78.87M | — | 78.87M | 10.00 | CO | British Virgin Islands | 2022-05-31 | ↗ |
| 13 | KKR China Healthcare Investment Limited | 22.90M | 23.80% | 22.90M | — | 22.90M | 10.00 | OO | Cayman Islands | 2012-05-01 | ↗ |
| 14 | Yuen KAM | 16.95M | 3.00% | 9.17M | 7.78M | 9.17M | 10.00 | IN | Hong Kong S.A.R. | 2014-08-25 | ↗ |
| 15 | Cordlife Group Limited | 16.12M | 18.10% | 16.12M | — | 16.12M | 10.00 | CO | Republic of Singapore | 2015-05-08 | ↗ |
| 16 | PAG | 9.50M | 7.80% | 9.50M | — | 9.50M | — | CO | Cayman Islands | 2023-02-03 | ↗ |
| 17 | PAG Asia Capital GP I Limited | 9.50M | 7.80% | 9.50M | — | 9.50M | — | CO | Cayman Islands | 2023-02-03 | ↗ |
| 18 | PAG Asia I LP | 9.50M | 7.80% | 9.50M | — | 9.50M | — | PN | Cayman Islands | 2023-02-03 | ↗ |
| 19 | PAG Capital Limited | 9.50M | 7.80% | 9.50M | — | 9.50M | — | CO | Cayman Islands | 2023-02-03 | ↗ |
| 20 | PAGAC III Holding VII Limited | 9.50M | 7.80% | 9.50M | — | 9.50M | — | CO | British Virgin Islands | 2023-02-03 | ↗ |
| 21 | Pacific Alliance Group Limited | 9.50M | 7.80% | 9.50M | — | 9.50M | — | CO | Cayman Islands | 2023-02-03 | ↗ |
| 22 | Magnum Opus International (PTC) Limited | 7.08M | 8.80% | 7.08M | — | 7.08M | 10.00 | CO | British Virgin Islands | 2015-02-10 | ↗ |
| 23 | Oasis Management Company Ltd. | 6.80M | 5.59% | — | 6.80M | — | 6.80M | IA | Cayman Islands | 2023-02-14 | ↗ |
| 24 | Seth Fisher | 6.80M | 5.59% | — | 6.80M | — | 6.80M | IN | Cayman Islands | 2023-02-14 | ↗ |
| 25 | Dendreon Pharmaceuticals LLC | 2.00M | 1.60% | — | 2.00M | — | 10.00 | OO | Delaware | 2022-09-23 | ↗ |
| 26 | Nanjing Xinjiekou Department Store Co., Ltd. | 2.00M | 1.60% | — | 2.00M | — | 10.00 | CO | of China | 2022-09-23 | ↗ |
| 27 | Nanjing Xinjiekou Department Store Co., Ltd. | — | 0.00% | — | — | — | 10.00 | CO | People’s Republic of China | 2022-05-20 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
506.5K
Shares Outstanding
133.91M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Bing Chuen Chen | Chief Financial Officer | 516.7K | male |
| Ting Zheng | Chief Executive Officer & CEO of Beijing Division | 516.7K | female |
| Rui Arashiyama | Chief Executive Officer of Guangdong & Zhejiang Divisions | 257.5K | female |
| Xin Xu | Chief Technology Officer | 122.8K | female |
| Cathy Bai | Vice President of Corporate Finance | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CORBF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
